From the source
From the source
Raises $2.1B in Series B funding led by Thrive Capital
Isomorphic Labs raised $2.1 billion in Series B funding, led by Thrive Capital, with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.
The company plans to use the capital to advance its AI drug design engine (IsoDDE) across multiple therapeutic areas and drug modalities.
From the source
Isomorphic Labs announces it has raised $2.1 Billion in Series B funding. The financing round is led by Thrive Capital, and includes participation from existing backers Alphabet and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, significantly expanding Isomorphic Labs’ global capital base.
isomorphiclabs.com
